Literature DB >> 20170949

Composite renal endpoints: was ACCOMPLISH accomplished?

Hiddo Lambers Heerspink1, Dick de Zeeuw.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20170949     DOI： 10.1016/S0140-6736(10)60098-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

1.  Putting ACCOMPLISH into context: management of hypertension in 2010.

Authors:  Finlay A McAlister; Robert J Herman; Nadia A Khan; Simon W Rabkin; Norm Campbell
Journal:  CMAJ       Date:  2010-09-13       Impact factor: 8.262

2.  Hypertension: antihypertensive class matters for combination therapy.

Authors:  William B White
Journal:  Nat Rev Cardiol       Date:  2010-06       Impact factor: 32.419

Review 3.  The kidney in type 2 diabetes therapy.

Authors:  Hiddo J Lambers Heerspink; Dick de Zeeuw
Journal:  Rev Diabet Stud       Date:  2011-11-10

4.  Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.

Authors:  T M E Davis; R Ting; J D Best; M W Donoghoe; P L Drury; D R Sullivan; A J Jenkins; R L O'Connell; M J Whiting; P P Glasziou; R J Simes; Y A Kesäniemi; V J Gebski; R S Scott; A C Keech
Journal:  Diabetologia       Date:  2010-11-04       Impact factor: 10.122

5.  Development of hyperkalemia following treatment with dapagliflozin (DAPA) in a patient with type 2 diabetes after bilateral adrenalectomy.

Authors:  Daichi Miyaoka; Akihiro Tsuda; Noriyuki Hayashi; Norikazu Toi; Akiyo Yamasaki; Yuki Nagata; Shinya Nakatani; Masafumi Kurajoh; Shinsuke Yamada; Tomoaki Morioka; Yasuo Imanishi; Masanori Emoto; Masaaki Inaba
Journal:  CEN Case Rep       Date:  2017-11-13

Review 6.  Optimal therapy in hypertensive subjects with diabetes mellitus.

Authors:  Gianpaolo Reboldi; Giorgio Gentile; Fabio Angeli; Paolo Verdecchia
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

7.  Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.

Authors:  H J Lambers Heerspink; D de Zeeuw; L Wie; B Leslie; J List
Journal:  Diabetes Obes Metab       Date:  2013-06-05       Impact factor: 6.577

8.  Clinical implications of the change in glomerular filtration rate with adrenergic blockers in patients with morning hypertension: the Japan morning surge-1 study.

Authors:  Seiichi Shibasaki; Kazuo Eguchi; Yoshio Matsui; Kazuyuki Shimada; Kazuomi Kario
Journal:  Int J Hypertens       Date:  2013-12-01       Impact factor: 2.420

9.  Chapter 3: Blood pressure management in CKD ND patients without diabetes mellitus.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.